Demographics and clinical characteristics of patients with suspected HIT
| Variable . | Total patients with HIT suspicions N = 113 . | Patients with non-HIT n = 70 . | Patients with HIT n = 43 . | P value . |
|---|---|---|---|---|
| Age, median [IQR], y | 65 [54-72] | 66 [53-72] | 65 [56-72] | .8 |
| Male sex, n (%) | 67 (59) | 41 (59) | 26 (60) | .8 |
| BMI, kg/m2 [IQR] | 26 [22-30] | 25 [22-28] | 28 [23-31] | .021 |
| Cardiovascular risk factors, n (%) | ||||
| Valvular heart disease | 20 (18) | 10 (14) | 10 (23) | .2 |
| Atrial fibrillation | 19 (17) | 13 (19) | 6 (14) | .5 |
| Chronic kidney disease | 15 (13) | 9 (13) | 6 (14) | .9 |
| Pulmonary embolism | 11 (10) | 8 (11) | 3 (7) | .5 |
| Deep venous thrombosis | 10 (9) | 7 (10) | 3 (7) | .7 |
| Acute coronary syndrome | 9 (8) | 7 (10) | 2 (5) | .5 |
| Heart failure | 6 (5) | 2 (3) | 4 (9) | .2 |
| Stroke | 7 (6) | 5 (7) | 2 (5) | .7 |
| Antithrombotic therapy at admission, n (%) | ||||
| Antiplatelet agents | .5 | |||
| Aspirin | 25 (22) | 15 (21) | 10 (23) | |
| Clopidogrel | 1 (1) | 1 (1) | 0 (0) | |
| Aspirin + clopidogrel | 4 (4) | 4 (6) | 0 (0) | |
| Therapeutic anticoagulation, n (%) | .1 | |||
| Apixaban | 9 (8) | 5 (7) | 4 (9) | |
| Rivaroxaban | 3 (3) | 2 (3) | 1 (2) | |
| Dabigatran | 1 (1) | 1 (1) | 0 (0) | |
| VKA | 5 (4) | 4 (6) | 1 (2) | |
| LMWH | 8 (7) | 8 (11) | 0 (0) | |
| UFH | 4 (4) | 4 (6) | 0 (0) | |
| Fondaparinux | 1 (1) | 1 (1) | 0 (0) | |
| Heparin therapy during hospitalization, n (%) | ||||
| LMWH | 70 (62) | 47 (67) | 23 (53) | .2 |
| UFH | 84 (74) | 46 (66) | 38 (88) | .007 |
| Variable . | Total patients with HIT suspicions N = 113 . | Patients with non-HIT n = 70 . | Patients with HIT n = 43 . | P value . |
|---|---|---|---|---|
| Age, median [IQR], y | 65 [54-72] | 66 [53-72] | 65 [56-72] | .8 |
| Male sex, n (%) | 67 (59) | 41 (59) | 26 (60) | .8 |
| BMI, kg/m2 [IQR] | 26 [22-30] | 25 [22-28] | 28 [23-31] | .021 |
| Cardiovascular risk factors, n (%) | ||||
| Valvular heart disease | 20 (18) | 10 (14) | 10 (23) | .2 |
| Atrial fibrillation | 19 (17) | 13 (19) | 6 (14) | .5 |
| Chronic kidney disease | 15 (13) | 9 (13) | 6 (14) | .9 |
| Pulmonary embolism | 11 (10) | 8 (11) | 3 (7) | .5 |
| Deep venous thrombosis | 10 (9) | 7 (10) | 3 (7) | .7 |
| Acute coronary syndrome | 9 (8) | 7 (10) | 2 (5) | .5 |
| Heart failure | 6 (5) | 2 (3) | 4 (9) | .2 |
| Stroke | 7 (6) | 5 (7) | 2 (5) | .7 |
| Antithrombotic therapy at admission, n (%) | ||||
| Antiplatelet agents | .5 | |||
| Aspirin | 25 (22) | 15 (21) | 10 (23) | |
| Clopidogrel | 1 (1) | 1 (1) | 0 (0) | |
| Aspirin + clopidogrel | 4 (4) | 4 (6) | 0 (0) | |
| Therapeutic anticoagulation, n (%) | .1 | |||
| Apixaban | 9 (8) | 5 (7) | 4 (9) | |
| Rivaroxaban | 3 (3) | 2 (3) | 1 (2) | |
| Dabigatran | 1 (1) | 1 (1) | 0 (0) | |
| VKA | 5 (4) | 4 (6) | 1 (2) | |
| LMWH | 8 (7) | 8 (11) | 0 (0) | |
| UFH | 4 (4) | 4 (6) | 0 (0) | |
| Fondaparinux | 1 (1) | 1 (1) | 0 (0) | |
| Heparin therapy during hospitalization, n (%) | ||||
| LMWH | 70 (62) | 47 (67) | 23 (53) | .2 |
| UFH | 84 (74) | 46 (66) | 38 (88) | .007 |
BMI, body mass index; LMWH: low-molecular-weight heparin; VKA, vitamin K antagonist.